<DOC>
	<DOCNO>NCT01766895</DOCNO>
	<brief_summary>The linkage viral hepatitis renal failure complex . The current study aim exlore long-term prevalence viral hepatitis among uremic patient Taiwan</brief_summary>
	<brief_title>Long-term Follow Up Viral Hepatitis Uremic Patients Taiwan</brief_title>
	<detailed_description>Patients prospectively recruit 15 hemodialysis unit include one medical center , 3 satellite hospital 11 local clinic Taiwan . Patients provide informed consent blood test include genetic study relate HCV spontaneous seroclearance enrol analysis . All eligible subject test HCV antibody ( third-generation , enzyme immunoassay ; Abbott Laboratories , North Chicago , IL ) hepatitis B surface antigen ( HBsAg ) . HCV RNA test polymerase chain reaction ( Cobas Amplicor Hepatitis C Virus Test , V.2.0 ; Roche Diagnostics , Branchburg , New Jersey , USA ; detection limit : 50 IU/ml ) twice least 6 month apart anti-HCV positive ensure chronicity HCV infection . HBsAg quantify use standard quantitative chemiluminescent microparticle immunoassay ( ARCHITECT HBsAg , Abbott Diagnostics ) . The concentration HBsAg specimen determine use previously generate Architect HBsAg calibration curve ( range , 0.05-250 IU/mL ) . Samples serum HBsAg titer &gt; 250 IU/mL dilute 1:20 1:500 Architect HBsAg diluent retested expand upper limit dynamic range 250 125,000 IU/mL . Serum HBV DNA determine standardize automate quantitative PCR assay ( Cobas Amplicor HBV Monitor ; Roche Diagnostics ; detection limit 200 copies/ml ) patient seropositive HBsAg .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Uremia</mesh_term>
	<criteria>uremic patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>uremia</keyword>
	<keyword>HBV</keyword>
	<keyword>HCV</keyword>
	<keyword>seroclearance</keyword>
</DOC>